Congestive vascular failure develops when ventricles unable to pump enough volume of blood to the body. Increase in the prevalence of cardiovascular diseases across regions is the major factors expected to drive the revenue growth of congestive vascular failure treatment globally. Lifestyle-related factors are expected to add to the growing disease incidence of CVDs. In addition, the growing number of obese patients is expected to bolster the congestive heart failure treatment market. The huge treatment demand for congestive vascular failure is expected to boost the treatment market. However, the availability of the generic drugs and lack of end-stage pipeline drugs and therapies for congestive vascular failure treatment is about to hinder the market.
HTML PDFShare this article
Journal of Blood & Lymph received 443 citations as per Google Scholar report
